A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation by Grassilli, E et al.
OPEN
ORIGINAL ARTICLE
A novel oncogenic BTK isoform is overexpressed in colon
cancers and required for RAS-mediated transformation
E Grassilli1,2, F Pisano1,2, A Cialdella1,2, S Bonomo1, C Missaglia1, MG Cerrito1, L Masiero1, L Ianzano1, F Giordano1, V Cicirelli1,
R Narloch1, F D’Amato3, B Noli3, GL Ferri3, BE Leone1, G Stanta4, S Bonin4, K Helin5,6,7, R Giovannoni1 and M Lavitrano1
Bruton’s tyrosine kinase (BTK) is essential for B-cell proliferation/differentiation and it is generally believed that its expression and
function are limited to bone marrow-derived cells. Here, we report the identiﬁcation and characterization of p65BTK, a novel
isoform abundantly expressed in colon carcinoma cell lines and tumour tissue samples. p65BTK protein is expressed, through
heterogeneous nuclear ribonucleoprotein K (hnRNPK)-dependent and internal ribosome entry site-driven translation, from a
transcript containing an alternative ﬁrst exon in the 5′-untranslated region, and is post-transcriptionally regulated, via hnRNPK, by
the mitogen-activated protein kinase (MAPK) pathway. p65BTK is endowed with strong transforming activity that depends on
active signal-regulated protein kinases-1/2 (ERK1/2) and its inhibition abolishes RAS transforming activity. Accordingly, p65BTK
overexpression in colon cancer tissues correlates with ERK1/2 activation. Moreover, p65BTK inhibition affects growth and survival of
colon cancer cells. Our data reveal that BTK, via p65BTK expression, is a novel and powerful oncogene acting downstream of the
RAS/MAPK pathway and suggest that its targeting may be a promising therapeutic approach.
Oncogene advance online publication, 25 January 2016; doi:10.1038/onc.2015.504
INTRODUCTION
Bruton’s tyrosine kinase (BTK) is a nonreceptor tyrosine kinase
initially identiﬁed as the defective protein in human X-linked
agammaglobulinemia.1 Since its discovery, BTK has been
considered a tissue-speciﬁc protein, being expressed throughout
the hematopoietic compartment, except T cells and plasma cells.
BTK plays a critical role in several hematopoietic signalling
pathways including those mediated by several chemokine
receptors and the B-cell antigen receptor.2 In B lymphocytes, as
an essential component of the B-cell signalosome, BTK is involved
in transducing activation, proliferation, maturation, differentiation
and survival signals and is an upstream activator of multiple anti-
apoptotic signalling molecules and networks, such as signal
transducer and activator of transcription 5, nuclear factor-κB and
the phosphatidylinositol-3-kinase/AKT/mammalian target of rapa-
mycin pathway.3 BTK is overexpressed in several B-cell
malignancies3 and different kinase-defective isoforms, exerting a
dominant-negative effect over full-length BTK, have been reported
in B-cell precursor leukaemia cells.4 Despite that its hyperactiva-
tion plays a pivotal role in chronic B-cell receptor signalling
required for the survival of neoplastic B cells and that in
experimental settings gain-of-function mutations providing BTK
with transforming potential have been described,2,5–7 no con-
stitutively active BTK mutants have been identiﬁed so far in
hematopoietic neoplasias, thus leaving the oncogenicity of BTK an
open question. BTK has emerged as a new molecular target for
the treatment of B-lineage leukaemias and lymphomas, and
Ibrutinib is the ﬁrst BTK-speciﬁc inhibitor that entered the clinic,
having been recently approved for the treatment of mantle cell
lymphoma and chronic lymphocytic leukaemia. Moreover, Ibruti-
nib and other BTK inhibitors are in advanced clinical trials for other
hematological malignancies.3
Here, we report the identiﬁcation of p65BK, a novel BTK isoform,
and show that it is expressed in colon cancers and that its
expression is regulated by its 5′-untranslated region (UTR) via
mitogen-activated protein kinase (MAPK)/heterogeneous nuclear
ribonucleoprotein K (hnRNPK)-dependent and internal ribosome
entry site (IRES)-driven translation of an alternatively spliced
mRNA. Moreover, we demonstrate that p65BTK is a novel and
powerful oncoprotein acting downstream of the RAS/MAPK
pathway and a mediator of RAS-induced transformation.
RESULTS
p65BTK is widely expressed in colon carcinoma cell lines and
tissues
Preliminary data from our laboratory indicated that, unexpectedly,
BTK is expressed in colon carcinoma cells, and thus we sought to
deﬁne its function in colonic tissue. First, we observed that BTK is
abundantly expressed in all colon cancer cell lines and tumour
tissues analysed (Figures 1a and b). While studying the expression
of BTK we noticed that its apparent molecular weight on SDS–
polyacrylamide gel electrophoresis was lower than expected
(Figure 1c). The downregulation of BTK expression by using
speciﬁc small interfering RNA (siRNA) conﬁrmed that the lower
band is encoded by the BTK gene (Figure 1d). As alternative
splicing of BTK mRNA has been reported in B-cell malignancies,4
we set out to identify the isoform expressed in colon cancers.
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Using a PCR strategy covering the entire coding sequence (CDS) of
BTK, we were unable to amplify the 5′ of the mRNA expressed in
colon cells (Supplementary Figures S1a and b). Indeed, 5′RACE
(rapid ampliﬁcation of cDNA ends)/sequencing experiments on
colon cancer cell line-derived complementary DNAs (cDNAs)
followed by ClustalW alignment (http://www.clustal.org/clustal2/)
(Supplementary Figures S1c and d) revealed that colon cancer-
derived mRNA contains a ﬁrst exon different from the one
expressed in B cells. Moreover, BLAST alignment showed that the
300 bp long exon mapped 15 192 bp upstream of the ﬁrst known
BTK exon (Supplementary Figure S1e). We named the exon ‘1b’,
whereas the known exon 1 was referred to as ‘exon 1a’. By using
isoform-speciﬁc siRNAs (Figure 1e) we conﬁrmed that the BTK
expressed in colon cancer cells is translated from exon 1b-
containing mRNA and, because of its apparent molecular weight,
we named it p65BTK. Analysis of p65BTK cDNA with an open
reading frame (ORF) predicting program8 revealed—beside the
expected starting codon in exon 2 (ATG1)—a putative start codon
in exon 4 (Figure 1f) whose usage would lead to a predicted
protein of ≈65 kDa. Transfection of 293T cells with a plasmid
expressing either a putative CDS starting from the ATG in exon 4
(ATG2) or the full-length cDNA led to the expression of ≈65-kDa
BTK (Figure 1g). Accordingly, siRNAs targeting exon 1b, but not
those targeting exon 1a, speciﬁcally abolished the synthesis of
65 kDa isoform in overexpressing 293T cells (Figure 1h). Compared
with the previously known isoforms, the predicted p65BTK protein
would lack most of the N-terminal Pleckstrin homology (PH)
domain (Figure 1h). To study the expression of the novel BTK
isoform we then raised and characterized BN49 polyclonal
antibody speciﬁc for p65BTK (Supplementary Figures S1f and g).
hnRNPK and active ERKs post-transcriptionally regulate p65BTK
expression
To further demonstrate p65BTK production from the identiﬁed
RNA we performed in vitro translation assays using a plasmid
containing p65BTK full-length cDNA. Surprisingly, in this setting
the protein was not translated, whereas small amounts of p65BTK
were obtained using a plasmid bearing either wild-type p77BTK
full-length cDNA or its mutated counterpart with a missense
mutation in the starting codon for 77 kDa BTK (ATG1) (Figure 2a).
Hence, within the context of p77BTK mRNA, the ATG2 can also be
recognized as a starting codon, although with much lower
efﬁciency.
The lack of p65BTK expression in cell-free systems, together
with the observation that the high levels of protein expression in
cancer tissues (Figure 1b) were not mirrored by increases of
Figure 1. p65BTK, a novel isoform of Bruton’s tyrosine kinase, is widely expressed in colon carcinoma cell lines and tissues. (a, b) BTK
expression in colon cancer cell lines (a) or patients’ biopsy (b) lysates. Western blots probed with a commercial BTK antibody (Santa Cruz,
sc-1696). (c) Western blot showing that in colon carcinoma cells (HCT116) BTK has a lower molecular weight than in lymphoid leukaemia
(Nalm-6). (d) Western blot of BTK expression in HCT116 cells after silencing with BTK-speciﬁc siRNA (exons 5+8). (e) Western blot of BTK
expression in HCT116 cells upon silencing using exon 1b (B1–3)-targeting siRNAs. (f) BTK gene and mRNAs encoding p77BTK and p65BTK.
ATG1 and ATG2: start codons, black/white boxes: translated/untranslated exons. Exon 1a and exon 1b are indicated. (g) BTK expression in
293T cells transiently transfected with empty vector (empty) and plasmids encoding p77BTK or p65BTK coding sequence (p77CDS, p65CDS),
p77BTK CDS or p65BTK CDS full lengths (p77FL, p65FL). (h) Western blot of p65BTK expression in 293T cells transiently transfected with p65FL
plasmid followed by silencing with exon1b-speciﬁc siRNAs. (i) p65 and p77 BTK protein organization: PH domain. BH, BTK homology region;
PPR, PolyProline region; TH, Tec homology domain; *phosphoinositide binding site.
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p65BTK mRNA expression in the same tissues (Figure 2b), led us to
hypothesize a post-transcriptional regulation mediated by a
cellular protein binding to the 5′UTR to promote the translation
of exon 1b-containing mRNA. Indeed, analysis of the 5′UTR
revealed the presence of four putative hnRNPK binding sites and
three upstream ORFs9 (Supplementary Figure S2a). hnRNPK is a
RNA-binding nuclear protein involved in chromatin remodelling,
transcription, splicing, translation and mRNA stability,10 over-
expressed and aberrantly localized in the cytoplasm in colorectal
cancers.11 Indeed, transfecting p65BTK-encoding plasmids
Figure 2. hnRNPK and active ERKs post-transcriptionally regulate p65BTK expression. (a) In vitro translation assay performed with the following
plasmids: empty vector (empty); p65FL (wt), p65_msATG1, p65_nsATG1, p65_nsATG2, p77_5′UTR or p77_msATG1. +cnt indicates the positive
control included in the commercial kit used for the reaction. (b) p65BTK mRNA expression in matched samples of tumoural and peritumoural
colon tissue from CRC patients (same patients as in Figure 1b). mRNA was quantiﬁed by Taqman assay and expression levels normalized to
phosphoglycerate kinase. (c) Western blot of 293T cells transfected with empty vector (empty) or the following plasmids: p65FL, p65_5′
UTRΔK1, p65_5′UTRΔK2, p65_5′UTRΔK3, p65_5′UTRΔK4. Deletion of all four binding sites allowed p65BTK overexpression most likely by
rendering the transcript as it would be a CDS. (d) Western blot of p65BTK levels in colon cancer cell lines after siRNA-mediated depletion of
hnRNPK (K). Transfection with siRNAs targeting luciferase (luc) was used as a control. On the right, the percentage of hnRNPK and p65BTK
protein expression of each sample as calculated and normalized to actin by ImageJ program (http://imagej.nih.gov/ij/). (e, top) Anti-hnRNPK
and anti-phospho-hnRNPK western blots after RNA immunoprecipitation using anti-hnRNPK and isotype-matched control (Ig mouse)
antibodies. (e, bottom) Real-time PCR of p65BTK mRNA recovered by RIP in hnRNPK and IgG immunoprecipitates. (f) Western blot of p65BTK
expression and hnRNPK-Ser284 phosphorylation following ERK1/2 inhibition with the MEK1/2 inhibitor CI-1040 (10 μM). Levels of total and
phospho-ERKs are also shown. Cell lysates were obtained 24 h after CI-1040 addition but for HCT116p53KO cells, where p65BTK reduction is
most prominent, at 16 h. On the right, the percentage of p-hnRNPK and p65BTK protein expression of each sample was calculated and
normalized to actin by ImageJ program.
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progressively deleted of the hnRNPK binding sites hampered its
overexpression (Figure 2c). Moreover, p65BTK expression in colon
cancer cells decreased upon silencing of hnRNPK by RNA
interference (Figure 2d).
Analysis of p65BTK 5′UTR by a RNA structure prediction
software (Supplementary Figure S2b) revealed a complex folding
pattern, with the ATG1 hidden in a hairpin loop. We therefore
hypothesized that 5′UTR-bound hnRNPK would promote a three-
dimensional structure favouring the ribosome to start the
translation from ATG2.
We then performed RNA immunoprecipitation (RIP) experiments
to conﬁrm the direct interaction of hnRNPK with p65BTK-encoding
mRNA (Figure 2e). Previous results have shown that signal-
regulated protein kinase-1/2 (ERK1/2)-mediated Ser284 phosphor-
ylation leads to the relocalization of hnRNPK from the nucleus to
the cytoplasm, where it accumulates12 and increases MYC mRNA
translation.13 Interestingly, we also showed that hnRNPK (bound
to p65BTK-enconding mRNA) is phosphorylated (Figure 2e), and
we therefore investigated whether ERK1/2 might regulate p65BTK
expression. As shown in Figure 2f, ERK1/2 inhibition (by MEK1/2
inhibitor CI-1040) indeed led to the decrease of both hnRNPK-
Ser284 phosphorylation and p65BTK.
Taken together, these results demonstrate that p65BTK levels
are regulated by both hnRNPK and active ERK1/2.
hnRNPK post-transcriptionally regulates p65BTK expression via
IRES-dependent translation of exon 1b-containing mRNA
The presence of several ORFs in the 5′UTR of p65BTK together
with the fact that MYC translation in leukemic cells is hnRNPK
dependent and IRES mediated13 led us to investigate whether
p65BTK translation is also driven by an IRES. We identiﬁed a
putative IRES in the 5′UTR of p65BTK mRNA (Supplementary
Figures S3a and b) and showed that eIF4G2, a translation
initiation factor involved in IRES-mediated translation,14
co-immunoprecipitates with hnRNPK and p65BTK-encoding
mRNA (Figure 3a). Next, we veriﬁed the presence of an IRES in
the 5′UTR by demonstrating green ﬂuorescent protein (GFP)
expression following transfection of HeLa cells with a bicistronic
vector in which GFP translation is under the control of p65BTK 5′
UTR (Figure 3b). Accordingly, GFP expression increased when the
experiment was repeated in the presence of 200 nM Rapamycin—
which blocks cap-dependent translation and stimulates
IRES-mediated translation15—and was abolished by 200 nm
Cymarin—a cardiac glycoside recently identiﬁed as a potent
inhibitor of MYC IRES-mediated translation16 (Figure 3b). The
presence of a cryptic promoter was ruled out by showing that a
unique transcript coding for both red ﬂuorescent protein (RFP)
and GFP is transcribed in transfected cells (Supplementary
Figure S3c). Finally, IRES-mediated translation of endogenous
p65BTK was conﬁrmed by demonstrating a time-dependent
increase and decrease of p65BTK levels on treatment of colon
cancer cells with Rapamycin and Cymarin, respectively (Figure 3c).
Notably, in reporter assay we also demonstrated that hnRNPK is
required for IRES-mediated translation of GFP, as its depletion by
siRNA (Figure 3d) as well as the deletion of all hnRNPK binding
sites (Supplementary Figure S4), completely abolished GFP
expression.
Altogether, these data demonstrate that IRES-mediated transla-
tion of p65BTK mRNA strictly depends on hnRNPK.
p65BTK is a novel oncogenic protein acting downstream of
RAS/ERK pathway and is overexpressed in colon cancers
In view of the abundant expression of p65BTK in colon carcinomas
and its IRES-mediated translation,17 we suspected that p65BTK
could have oncogenic properties. Indeed, transfection of a
plasmid encoding full-length p65BTK (Figures 4a–d) transformed
NIH3T3 ﬁbroblasts, whereas p77BTK overexpression did not
(Figure 4d). Notably, p65BTK was more potent than H-RASV12,
used as a positive control, inducing more and larger colonies and
foci. Inhibition of p65BTK-mediated transformation by use
of the speciﬁc BTK inhibitor Ibrutinib3,18,19 indicated that
p65BTK oncogenic capacity is dependent on its kinase activity.
Moreover, Ibrutinib addition also blocked H-RASV12-mediated
transformation (Figure 4d). Interestingly, we found that BTK
overexpression in NIH3T3 cells induced high levels of endogenous
RAS (Figure 4a). Even though wild-type RAS overexpression is not
transforming,20–23 its expression appeared necessary for p65BTK-
mediated transformation, as the RAS inhibitor FTI277, as well as
cotransfection with a RAS-DN plasmid, abolished p65BTK-
mediated transformation of NIH3T3 cells (Figure 4d and
Supplementary Figure S5b). Conversely, H-RASV12 overexpression
increased endogenous p65BTK (Figure 4a) and endogenous RAS
knockdown rapidly depleted p65BTK (Supplementary Figure S5a),
conﬁrming that RAS indeed regulates p65BTK expression.
However, p65BTK silencing did not affect endogenous RAS
expression (Supplementary Figure S5a), suggesting that the
observed endogenous RAS induction in p65BTK-transfected
NIH3T3 cells is an effect of exogenous p65BTK overexpression.
Finally, p65BTK-mediated transformation was suppressed when
blocking RAS/MAPK pathway downstream of RAS, namely by
using MEK1/2-inhibitor CI-1040 (Figure 4d). Altogether, these data
indicate that p65BTK is an obligate effector of activated RAS.
We then conﬁrmed our results showing that p65BTK expression
parallels ERK1/2 activation and abnormal hnRNPK cytoplasmic
localization by immunohistochemical analysis on paired peritu-
moural/tumoural samples from the same 13 colon carcinoma
patients whose tissues have already been analysed for p65BTK
expression in Figures 1b and 2b (Figure 4e, Supplementary
Figure S6 and Supplementary Table S1).
Furthermore, we analysed p65BTK expression in a cohort of 83
stage II colon carcinoma patients and found that in 68.7% of
peritumoural/tumoural sample pairs, p65BTK was more expressed
in tumoural than in peritumoural tissue (Figure 4f); in addition, the
grading of p65BTK according to an increasing intensity of the
staining in tumoural samples (Supplementary Figure S7) showed
moderate to high levels of the protein in the 74.7% of colon
cancer tissues analysed (Figure 4g).
Taken together, our results suggest that p65BTK is an
oncoprotein whose expression and transforming activity are
tightly controlled, via hnRNPK, by the RAS/ERK pathway and that
p65BTK overexpression in colon carcinomas reﬂects hyperactiva-
tion of the RAS/ERK pathway.
p65BTK inhibition affects growth and survival of colon cancer cells
Finally, we tested the requirement of p65BTK in colon cancer
cell biology. For all colon cancer cell lines tested, in vitro
dose–response experiments showed that concentrations up to
10 μM Ibrutinib caused a slight to moderate decrease in
proliferation in the short term (Figure 5a) and strongly affected
clonogenicity in the long term (Figure 5b); higher doses further
inhibited the proliferation of all cell lines and completely
suppressed cell growth at 30 μM (Figures 5a and c) concomitantly
with a signiﬁcant increase of cell death (Supplementary Figure S8a).
Similar results were obtained treating colon cancer cell lines with
AVL-292, a different BTK inhibitor also in clinical trials for treating
B-cell malignancies.19 Notably, AVL-292 at 10 μM almost comple-
tely suppressed cell growth and had a mild but signiﬁcant
cytotoxic effect (Supplementary Figure S8b) that increased in a
dose-dependent manner (Supplementary Figure S8c).
DISCUSSION
Since its discovery, BTK has been considered a tissue-speciﬁc
kinase expressed only in bone marrow-derived cells.2 In particular,
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BTK transduces essential signals for the proliferation and
differentiation of B lymphocytes and it has been found over-
expressed/constitutively active in several B-lineage lymphoid
malignancies.3 Here we report the identiﬁcation and characteriza-
tion of p65BTK, a novel oncogenic isoform, whose 5′UTR-
regulated expression is ﬁnely tuned downstream of ERK1/2
activation via hnRNPK- and IRES-dependent translation, whose
activity is required for H-RASV12-induced transformation and
whose levels are increased in a high percentage of colon cancers.
The most striking ﬁnding of this paper is that not only is BTK
expressed outside of the hematopoietic compartment but, via
p65BTK expression, is also a potent oncogene. Different kinase-
defective isoforms of BTK have been reported in B-cell precursor
leukaemia cells,4 and an 80-kDa isoform, bearing an extended
N-term domain, has been demonstrated in breast carcinoma
cells24 and at least three other protein-coding splice variants can
be predicted by the Ensembl automatic gene annotation system
(http://www.ensembl.org/Homo_sapiens/Transcript/Summary?db=
core;g=ENSG00000010671;r=X:101349447-101386224;t=ENST00000
621635). However, this is the ﬁrst time that the expression of an
isoform lacking most of the PH domain is found (Figure 1). By
binding phosphatidylinositol-3-kinase-generated phosphatidylino-
sitol-3,4,5-trisphosphate, PH domain allows BTK translocation to
the plasma membrane and its activation.2 Several other proteins
have been reported to interact with BTK via the PH domain, most
of them negative regulators: protein kinase C-β binding interferes
Figure 3. hnRNPK post-transcriptionally regulates p65BTK expression via IRES-dependent translation of exon 1b-containing mRNA. (a) Anti-
hnRNPK antibodies immunoprecipitate a complex containing hnRNPK, eIF4G2 (top) and p65BTK mRNA (bottom) from HCT116p53KO lysates.
(b) Fluorescence of HeLa cells transfected with a bicistronic vector encoding RFP under the control of CMV promoter and GFP not
preceded by a regulatory region (ﬁrst row) or under the control of p65BTK 5′UTR (second to fourth row) and left untreated (second row) or
treated with Rapamycin 200 nM (third row) or Cymarin 100 nM (fourth row) for 36 h. DAPI was used to stain nuclei. (c) Time-dependent
variation of p65BTK expression after treatment of colon cancer cells with 200 nM Rapamycin (left) and 200 nM Cymarin (right). Fold variation of
p65BTK protein expression of each sample was calculated and normalized to actin by ImageJ program. (d) HeLa cells were transfected with
the same bicistronic reporter as in (b) and luc-targeted siRNAs (second row) or hnRNPK-targeted siRNAs (third row). DAPI was used to stain
nuclei.
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with plasma membrane targeting and subsequent activation of
BTK;25,26 inhibitor of BTK physically associates with BTK and
downregulates its kinase activity;27,28 the peptidyl-prolyl cis-trans
isomerase Pin1, by binding to S21 and S115, leads to the
destabilization of the protein.29 It is therefore likely that because
of the absence of most of the PH domain, p65BTK would be
regulated/activated differently than p77BTK, as well as be involved
in different signalling pathways. Moreover, lacking the region
responsible for its negative regulation, it may be expected that
p65BTK would be abundantly expressed and activated. Indeed, at
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variance with p77BTK, p65BTK is endowed with a strong
transforming activity (Figure 4). The transforming potential of
BTK has been matter of debate since its discovery and has never
been completely resolved. It has been demonstrated that gain-of-
function mutations introduced experimentally in the PH domain
provide BTK with transforming potential;2,5–7 however, no con-
stitutively active BTK mutants have been identiﬁed so far in
hematopoietic neoplasias, although it has been extensively shown
that p77 plays pro-survival and anti-apoptotic roles in B cells.2,3
Recently, a 80-kDa isoform, bearing an extended N-term, has been
identiﬁed by Eifert et al.24 in breast carcinoma cells having, similar
to p77BTK, pro-survival and anti-apoptotic roles. As for the
transforming potential of BTK, our results clearly indicate that
overexpression of p77BTK is not transforming, whereas over-
expression of p65BTK is even more powerful than H-RASV12 in
transforming NIH-3T3 cells (Figures 4c and d). We therefore
conclude that BTK is indeed an oncogene, being its transforming
activity carried out by the p65, but not the p77, isoform.
A main point of the paper is that p65BTK expression and
oncogenicity result from RAS/ERK pathway activation (Figure 6).
Several lines of evidence demonstrate that p65BTK (over)
expression is controlled, via hnRNPK, by the RAS/ERK pathway.
p65BTK mRNA-bound hnRNPK is phoshorylated on Ser284
(Figure 2e), a residue known to be phosphorylated by ERK1/
2.12,13 Accordingly, upon blocking ERK1/2 activation p65BTK levels
decreased concomitantly to hnRNPK-p-Ser284 reduction
(Figure 2f). Notably, ERK1/2-mediated Ser284 phosphorylation
leads to the relocalization of hnRNPK from the nucleus to the
cytoplasm12 and a cytoplasmic localization is necessary for
hnRNPK to participate in p65BTK mRNA translation. In addition,
p65BTK-mediated transformation is suppressed in the presence of
CI-1040 but resumes when the inhibitor is removed from the
medium (Figure 4d), consistent with a restart of ERK/hnRNPK-
mediated translation of p65BTK mRNA. Accordingly, also blocking
the RAS/ERK pathway upstream of ERK1/2, that is, by inhibiting
endogenous RAS either by use of a chemical inhibitor or a RAS-
DN, abolished p65BTK-mediated transformation of NIH-3T3 cells
(Figure 4d and Supplementary Figure 5b). Even though it has been
demonstrated that overexpression of wild-type RAS, at variance
with mutated RAS, does not transform NIH3T3 cells,20–23 a
p65BTK-mediated increase in endogenous RAS levels may
enhance p65BTK transforming activity by triggering a positive
feedback loop. A possibility might be that p65BTK directly, or via
one or more effector(s), induces RAS expression or blocks its
degradation: such a mechanism would justify the stronger
transforming activity of p65BTK compared with H-RASV12.
Additional studies are required to ascertain this hypothesis.
Conversely, p65BTK inhibition (Figure 4d) also prevented
H-RASV12-mediated transformation, indicating that p65BTK is a
pivotal downstream effector of RAS and conﬁrming that its
transforming activity depends on the RAS/ERK pathway. Finally,
we showed in paired peritumoural/tumoural samples from colon
carcinoma patients that p65BTK expression parallels ERK1/2
activation and abnormal hnRNPK cytoplasmic localization
(Figure 4e). A further indication that p65BTK is key effector in
the RAS/ERK pathway is given by the results obtained on its
inhibition in colon cancer cells. It is well known that the RAS/ERK
pathway is critical for transducing mitogenic signals and regulat-
ing cell proliferation.30 Accordingly, p65BTK inhibition profoundly
affects proliferation and clonogenicity of all colon cancer cells
tested (Figure 5). Given that deregulation of the RAS/ERK
pathway31 occurs at high frequency in colon cancers, our data
indicate that p65BTK might be a novel promising therapeutic
target in this kind of tumours.
A comprehensive analysis of the mammalian transcriptome
showed that most genes allow the expression of alternative
5′UTRs resulting either by use of multiple transcriptional start sites
or by differential splicing.32 Alternative 5′UTRs may allow
transcript isoforms to bind different RNA-binding proteins, thus
leading to tissue-speciﬁc or stage-speciﬁc expression.33 Moreover,
inappropriate expression of alternative 5′UTRs can contribute to
tumourigenesis as in case of alternative 5′UTRs regulating the
translation of BRCA1, MDM2 and transforming growth factor-β.32
All the examples reported so far in the literature show that tissue-
speciﬁc, stage-speciﬁc or inappropriate expression of transcripts
bearing alternative 5′UTRs control the expression of the same
CDS, making it subject to developmental, physiological or
pathological regulation. Our results demonstrate for the ﬁrst time
that alternative 5′UTRs can contribute to the diversiﬁcation of
gene expression by also driving the production of different
protein isoforms, endowed with different functions.
Several oncogenic proteins can be translated by both cap-
dependent and IRES-dependent mechanisms, the latter being
switched on to maintain the expression of speciﬁc proteins during
pathological situations when cap-dependent translation is
compromised.34 Interestingly, p65BTK translation is strictly IRES
dependent (Figures 3b and c), suggesting that its expression
should be very low in physiological conditions or in nontrans-
formed cells. Moreover, in the 5′UTR of p65BTK mRNA, three
upstream ORFs are present (Supplementary Figure S2a) that, in
unstressed conditions, reduce the efﬁciency of translation initia-
tion of the main downstream ORF.35 Indeed, basal levels of
p65BTK are low in immortalized NIH-3T3 cells (Figure 4a) and very
low or undetectable in peritumoural samples (Figures 1b and 4e
and Supplementary Figure S6). Translational control is a crucial
component of cancer development and progression, and a role for
RAS/ERK signalling pathway in the regulation of cap-dependent
translation via its action on mammalian target of rapamycin
Figure 4. p65BTK is a novel oncogenic protein acting downstream of RAS/MAPK pathway and is overexpressed in colon cancers. (a) NIH3T3
cells transfected with empty vector or plasmids encoding p65BTK, p77 or mutated H-RAS (H-RASV12). p65BTK expression was assessed by
p65BTK-speciﬁc polyclonal antibody BN49, whereas p77BTK was probed with a monoclonal antibody against the N-term of BTK (BD). (b) Phase
contrast images of NIH3T3 transfected with empty vector or plasmids expressing p77BTK, p65BTK, H-RASV12; × 40 magniﬁcation. To note,
p77BTK-transfected NIH3T3 maintain the same appearance of the empty vector-transfected untransformed ﬁbroblasts, whereas p65BTK-
transfected NIH3T3 are similar to H-RASV12-transformed ﬁbroblasts. (c) In soft agar assay, p65BTK-transfected NIH3T3 ﬁbroblasts showed a
colony-forming activity higher than H-RASV12-transfected ones (×10 magniﬁcation). Right: number of colonies (mean of three separate wells).
(d) Focus assay of NIH3T3 cells transfected with empty vector, H-RASV12, p65BTK or p77BTK expression plasmids, grown in the absence or
presence of BTK (Ibrutinib), RAS (FTI-277) or MEK1/2 (CI-1040) inhibitors; parallel samples of p65BTK-transfected cells were treated for 16 days
with CI1040 or treated for 10 days with CI1040 followed by 6 days without drug; (×10 magniﬁcation). (e) Immunohistochemical detection of
p65BTK, hnRNPK and p-ERK-1/2 in formalin-ﬁxed, parafﬁn-embedded specimens (×40 magniﬁcation); tumour samples (T) showing
predominant cytoplasmic hnRNPK expression and moderate to strong p-ERK-1/2 levels expressed the highest amounts of p65BTK, whereas
low expression of p65BTK was detectable in peritumoural (PT) samples, in which hnRNPK was exclusively or predominantly nuclear and
p-ERK-1/2 levels were very low. (f, g) Overexpression of p65BTK in patients with stage II colon cancer. Tissue microarray (TMA) analysis of
p65BTK expression was performed in tumoural/peritumoural pairs of specimens from a cohort of 83 patients and results were grouped by
comparing the expression in tumoural vs peritumoural tissues (f) and by the intensity of the staining in the tumour tissue (g).
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Figure 5. p65BTK inhibition affects growth and survival of colon cancer cells. (a) Time course showing Ibrutinib dose response (0, 0.01, 0.1, 1,
10, 20 μM Ibru) of colon carcinoma cell lines characterized by different genetic background; cell proliferation was determined every 24 h by
MTT assay on cells incubated with Ibrutinib at the indicated concentrations; error bars show s.e.m.; data are the average of 3–5 independent
experiments. Ibrutinib at 10 and 20 μM signiﬁcatively decreases cell growth in all cell lines *10 vs 0 μM Ibru Po0.05; **20 vs 0 μM Ibru: Po0.05.
(b) Clonogenicity was assessed by seeding cells at low density and incubating them with the indicated doses of Ibrutinib for 10–12 days, at
the end of which colonies were stained by crystal violet. (c) Cell viability was assessed after 72 h of treatment with the indicated concentration
of Ibrutinib; crystal violet assay was performed to quantify viable cells; data are presented as fold change of the initial cell number obtained
from 3 independent experiments; error bars show s.e.m. *10 vs 0 μM Ibru: Po0.05; **20 vs 0 μM Ibru: Po0.05; ***30 vs 0 μM Ibru: Po 0.05.
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complex 1 is well accepted.36 Our data about ERK/hnRNPK-
dependent regulation of IRES-driven translation of p65BTK,
together with the demonstration that RAS-induced transformation
requires p65BTK, suggest that RAS/ERK signalling, via hnRNPK,
may also play a crucial role in the regulation of IRES-dependent
translation and that disregulation of IRES-mediated translation
may be a feature of cancer cells with an hyperactive RAS/ERK
pathway (like colon cancer cells).
In conclusion, we show that a novel isoform of BTK is expressed
outside of the hematopoietic compartment as a result of a
complex post-transcriptional mechanism, and we provide evi-
dence that alternative 5′UTRs can contribute to the diversiﬁcation
of gene expression by driving the production of different protein
isoforms, endowed with different transforming potential. More-
over, our results demonstrating that BTK is a potent oncoprotein
acting downstream of the RAS/ERK pathway, together with those
showing that its inhibition profoundly affects colon cancer cells
proliferation and survival, suggest that p65BTK might be a novel
promising therapeutic target in colon cancer, where deregulation
of the RAS/ERK pathway occurs at a very high frequency.
MATERIALS AND METHODS
Plasmids
Standard cloning methods were used to generate all plasmids, whereas
50 RACE was performed to clone 50 end of p65BTK mRNA. Detailed
methods are described in the Supplementary Methods.
Cell lines, culture and treatments
Isogenic p53wt (HCT116) and p53KO (HCT116p53KO) HCT116 colon
carcinoma cell lines were from Dr Bert Vogelstein (Johns Hopkins
University, Baltimore, MD, USA) through the GRCF Biorepository & Cell
Center of the John Hopkins School of Medicine. The 293T, HeLa, DLD-1,
SW480, RKO, T84, HT-29, SW948, SW620, SW48, LoVo, CaCo-2 and NIH3T3
and HeLa cells were from American Type Culture Collection
(LGC Standards, Sesto San Giovanni, Italy). Nalm-6 were from Deutsche
Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig,
Germany). All the repositories guaranteed cell line identity by genotypic
and phenotypic testing. Upon arrival, cells were expanded and frozen as
seed stocks of ﬁrst or second passage. All cells were passaged for a
maximum of 6 weeks, after which new seed stocks were thawed for
experimental use. All cells were grown at 37 °C in 5% CO2 and were
maintained as a subconﬂuent monolayer in McCoy medium (HCT116,
HCT116p53KO, DLD-1, SW480, HT-29, SW620), Dulbecco’s modiﬁed Eagle’s
medium/Ham’s F12 (T84), RPMI-1640 (Nalm-6, SW48, SW948), Ham’s F12
(LoVo) or Dulbecco’s modiﬁed Eagle’s medium (NIH3T3, 293T, HeLa, RKO,
Caco-2) supplemented with 10% fetal bovine serum (except for NIH3T3
cells medium, supplemented with 10% calf serum) and 1% penicillin/
streptomycin; 1% nonessential amino acids was also added to RKO and
Caco-2 medium. Cells were routinely checked for mycoplasma contamina-
tion each time a new stock was thawed. Media, serum and supplements
were all from Invitrogen (Life Technologies Italia, Monza, Italy) except for
calf serum (Colorado Serum Company, Denver, CO, USA). Ibrutinib and
AVL-292 (Selleckchem, Houston, TX, USA) were dissolved in dimethyl
sulfoxide and stored in aliquots at − 80 °C.
Transfection and silencing experiments
The siRNA and plasmid transfections were performed using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions. Silencing
experiments and siRNA sequences are described in detail in
Supplementary Information. Each transfection and silencing experiment
was repeated at least three times.
Cell transformation assays
Focus assay. NIH3T3 cells were seeded at 70% conﬂuency in a 6-well
plate the day before and then were transfected using Lipofectamine 2000
and 4 μg DNA/well; 36 h after transfection, cells were reseeded in triplicate
in 6-well plate in the presence or absence of inhibitors of BTK (Ibrutinib,
10 μM), RAS (FTI-277, 10 μM) and MEK1/2 (CI-1040 10 μM). Inhibitors were
replenished each day, whereas medium was changed every other day.
After 10 days, foci were ﬁxed and stained in 1% crystal violet, 35%
ethanol. Parallel samples of p65BTK-transfected cells were treated for
16 days with CI1040 or treated for 10 days with CI1040 followed by 6 days
without drug.
Soft agar assay. An aliquot (1000 cells) of NIH3T3 cells transfected as
above were resuspended in warm (37 °C) 0.4% Top Agar Solution and
seeded on a solidiﬁed 0.8% Base Agar Solution, both prepared according
to the protocol of the Cell Transformation Detection Assay (Merck-
Millipore, Vimodrone, Italy). Cells were fed every 3 days with cell culture
medium and colonies counted after 10 days by 3 independent evaluators.
Cell transformation assays were repeated three times.
Cell growth/proliferation assay
5× 103 cells per 96-well plate were seeded in triplicate, and starting the
following day (day 0) proliferation was evaluated every 24 h using a MTT-
based assay (Sigma-Aldrich, Milano, Italy) according to the manufacturer’s
instructions. Graphs represent the average of three to ﬁve independent
experiments. Average± s.e.m. are plotted in the graphs.
Colony assay
Cells were seeded at low density (1000 cells/well in 6-well plate) in
triplicate and left untreated or treated with different concentrations of
Ibrutinib. Medium (alone or contanining Ibrutinib) was replaced every
other day, and after 10 days colonies were ﬁxed and stained in 1% crystal
violet, 35% ethanol. Colony assays were repeated three times.
Cell viability
Cells were seeded in sextuplicates at 70% conﬂuency the night before and
the next morning treated or not with the indicated concentrations of
Ibrutinib. After 72 h, cell viability was evaluated by crystal violet staining.
Brieﬂy, after washing with phosphate-buffered saline, cells were ﬁxed/
stained with a solution of 0.5% crystal violet in 20% methanol for 20 min at
room temperature and then washed extensively with tap water. Colour
was extracted by adding 0.1 M acetic acid and quantiﬁed by spectro-
fotometer at 595 nm. Graphs represent the average of three separate
experiments. Average± s.e.m. are plotted in the graphs.
GFP/RFP ﬂuorescence assay
Cells transfected with GFP/RFP bicistronic vectors were harvested after
36 h, ﬁxed with 4% paraformaldehyde in phosphate-buffered saline and
counterstained with DAPI (40 ,6-diamidino-2-phenylindole). Fluorescence
microscope examination was performed using a Nikon Eclipse 80i
microscope at × 60 magniﬁcation. Images were acquired using Genikon
Figure 6. Proposed model of p65BTK regulation.
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(Nikon Instruments, Campi Bisenzio, Italy) software and processed with
Adobe Photoshop. GFP/RFP ﬂuorescence assays were repeated
three times.
Tissue samples
Permission for using tissue specimens surgically removed from patients
was granted by the ethical committee of the University of Milano-Bicocca.
Multiple specimens, collected from patient admitted to Desio Hospital
(n=13, for patient characteristics see Supplementary Table S1), were
dissected by a pathologist from matched peritumoural/normal tissues
removed during surgery and either immediately frozen at − 80 °C for RNA
and protein analysis or routinely ﬁxed in formalin for subsequent
hystological and immunohistochemistry analysis on tissue microarray.
Frozen specimens were used to measure p65BTK expression by
quantitative PCR after processing with RNeasy kit (Qiagen, Milano, Italy)
and by western blot upon tissue lysis in RIPA buffer, as described below. In
a separate analysis, tissue microarray samples from a cohort composed of
83 patients (admitted to Trieste University Hospital; for patients
characteristics see Supplementary Table S1) with a clinical diagnosis of
colon cancer, classiﬁed by a pathologist as stage II, were examined for
p65BTK expression by immunohistochemistry.
Immunohistochemistry
Specimens from patients admitted to Desio Hospital (n=13) were ﬁxed
with formalin, dehydrated, diaphanized with xylene, put in parafﬁn and
processed for tissue microarray. Slides were stained according to standard
immunohistochemistry procedures with the following primary antibodies:
anti-hnRNPK (sc-25373) from Santa Cruz Biotechnologies (Heidelberg,
Germany); phospho-ERK (Thr202/Tyr204) (#4370) from Cell Signaling
(Danvers, MA, USA); and anti-p65BTK BN49 polyclonal antibody. Slides
were digitally acquired using Aperio ScanScope System (Leica Micro-
systems, Milano, Italy). On specimens from patients admitted to Trieste
University Hospital (n=83), p65BTK staining was graded accordingly to an
increasing intensity by blind reading by two experienced operators and
classiﬁed as negative, positive and strongly positive.
RNA extraction and RIP
RNA was isolated using an RNeasy kit (Qiagen) following the manufac-
turer’s instructions. In RIP experiments, RNA was puriﬁed from anti-hnRNPK
(ab39975, Abcam, Cambridge, UK) immunoprecipitated complex from
colon cancer cell (HCT116p53KO) lysates using the Magna RIP kit (Millipore,
Vimodrone, Milano, Italy) following the manufacturer’s instructions. Isotype
matched antibodies were used as a control. RIP experiments were
repeated three times.
PCR
End point PCR, 5′RACE PCR and real-time PCR procedures and primers are
described in Supplementary Information.
Anti-p65BTK antibody production and characterization
BN49 polyclonal antibody produced by immunizing rabbits with a GST
fusion protein encompassing the ﬁrst 30N-term aa of p65BTK absorbed to
nanogold.37 Antisera speciﬁcity was assessed by western blot analysis on
lysates from p65BTK-expressing and p65BTK-silenced cells (Supplementary
Figure 1f) and used in all western blots to probe p65BTK unless differently
speciﬁed. In immunocytochemistry, speciﬁcity was additionally tested
using pre-immune serum, as well as by pre-absorption with corresponding
synthetic peptide/s (up to ∼ 50 nmol/ml) on sections from cell blocks of
SW480 p65BTK-expressing and p65BTK-silenced cells (Supplementary
Figure 1g) and on sections from colon cancer patient tissues.
Western blot analysis
Protein extracts were prepared using high-salt lysis buffer (Hepes 50 mM,
pH 7.5, NaCl 500 mM, DTT 1 mM, EDTA 1 mM, 0.1% NP-40) supplemented
with 1% protease inhibitor cocktail (Sigma-Aldrich). Then, 10–20 μg cell
and tissues lysates were separated on 10% NuPAGE gels (Invitrogen),
transferred onto a nitrocellulose membrane (Invitrogen) and incubated
with the following antibodies: anti-p65BTK (BN49); anti-BTK (sc-1696)
anti-hnRNPK (sc-25373) from Santa Cruz Biotechnologies; anti-ERK (#9101),
anti-phospho-ERK (Thr202/Tyr204) (#4370), anti-eIF4G2 (#5169) from Cell
Signaling; anti-actin (A1978), anti-vinculin (V9264), anti-phospho-hnRNPK
(SAB4504229) from Sigma-Aldrich; and anti-RAS (#05-516) from Millipore.
Each single blot was reprobed with anti-actin or anti-vinculin as loading
control. Images were acquired using G:BOX XT4 Chemiluminescence and
Fluorescence Imaging System (Syngene, Cambridge, UK) and processed
with Adobe Photoshop.
In vitro translation
TnT Quick Coupled Transcription/Translation Systems (Promega, Milano,
Italy) has been used according to the manufacturer’s instructions. Brieﬂy,
1 μg each plasmid DNA was mixed with 12.5 μl Master mix from the kit and
1 μl Transcend Biotinylated tRNA (Promega). Translated products, sepa-
rated on NuPAGE and blotted onto nitrocellulose, were detected by
chemiluminescence upon incubation with the horseradish peroxidase/
streptavidine conjugate. The in vitro translation experiments were
repeated three times.
Statistical analysis
The t-test was applied to evaluate statistically signiﬁcant differences
between series of samples subjected to different experimental treatments,
and P⩽ 0.05 was considered signiﬁcant.
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